Assessment of the safety of regular DDAVP therapy in primary nocturnal enuresis.
A group of 7 patients with refractory primary nocturnal enuresis on long-term DDAVP therapy (mean 13 months) were submitted to a standard water deprivation test in conjunction with a hormone profile and routine haematological and biochemical investigations. No abnormalities were demonstrated, which suggests that the drug is safe in this clinical situation.
Rew
D A
DA
Department of Urology, Poole General Hospital.
Rundle
J S
JS
D000293:Adolescent; D000328:Adult; D002648:Child; D003894:Deamino Arginine Vasopressin / Q000009:adverse effects* / Q000627:therapeutic use; D004775:Enuresis / Q000188:drug therapy*; D005260:Female; D006801:Humans; D008297:Male; D010913:Pituitary-Adrenal System / Q000187:drug effects; D012449:Safety; D013997:Time Factors
D003894:Deamino Arginine Vasopressin